# Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

> **NCT05417594** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 695 (estimated)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** AZD9574
- **DRUG:** Temozolomide (TMZ)
- **DRUG:** [11C]AZ1419 3391
- **DRUG:** Trastuzumab Deruxtecan (T-DXd)
- **DRUG:** Datopotamab Deruxtecan (Dato-DXd)

## Key facts

- **NCT ID:** NCT05417594
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-24
- **Primary completion:** 2027-10-13
- **Final completion:** 2027-10-13
- **Target enrollment:** 695 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05417594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05417594, "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05417594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*